WHO ICTRP trial
Bevacizumab combined with afatinib for first-line treatment of locally advanced…
ChiCTR2000034451 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2000034451 |
|---|---|
| Public title | Bevacizumab combined with afatinib for first-line treatment of locally advanced or advanced EGFR mutation-positive NSCLC patients: the effectiveness and safety database management platform construction project |
| Scientific title | Bevacizumab combined with afatinib for first-line treatment of locally advanced or advanced EGFR mutation-positive NSCLC patients: the effectiveness and safety database management platform construction project |
| Primary sponsor | National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Countries | China |
| Conditions | NSCLC |
| Interventions | Case series:afatinib combined with bevacizumab |
| Registration date | Jul 5, 2020 |
| Target size | Case series:50 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: